SCH 58261

Known as: SCH-58261, SCH58261 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1996-2018
0102019962018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
Alzheimer's disease (AD) is characterized by memory impairment, neurochemically by accumulation of beta-amyloid peptide (namely… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Consumption of caffeine, an adenosine receptor antagonist, was found to be inversely associated with the incidence of Alzheimer's… (More)
Is this relevant?
2007
2007
The effect of chronic treatment with the selective adenosine A2A receptor antagonist SCH 58261 on the behavioral and… (More)
Is this relevant?
2006
2006
We investigated the protective effect of subchronic treatment of the A2A receptor antagonist, SCH 58261 (0.01 mg/kg, i.p… (More)
Is this relevant?
2001
2001
The aim of the present study was to find out whether blockade of adenosine A(2A) receptors by a selective antagonist, SCH 58261… (More)
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Recent epidemiological studies have established an association between the common consumption of coffee or other caffeinated… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
1999
1999
Three structurally related non-xanthine compounds, CGS 15943, ZM 241385 and SCH 58261, are potent A2A adenosine receptor… (More)
  • table 1
  • table 2
  • figure 1
Is this relevant?
Highly Cited
1998
Highly Cited
1998
Blockade of adenosine receptors can reduce cerebral infarct size in the model of global ischaemia. Using the potent and selective… (More)
Is this relevant?
1998
1998
We characterized the in vivo cardiovascular profile of SCH 58261, 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2, 4… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
1996
1996
We have characterized the in vitro pharmacological profile of the new potent and selective A2a adenosine receptor antagonist SCH… (More)
Is this relevant?